Multimodality cardiac imaging, particularly echocardiography and cardiovascular magnetic resonance, plays a central role in the diagnosis, prognostic assessment, and follow-up of Fabry disease.
Multimodality imaging, particularly echocardiography and CMR, plays a central role in the early recognition, differential diagnosis, and prognostic assessment of Fabry disease.
Fabry disease (FD) is a genetic lysosomal storage disease with frequent cardiovascular involvement, whose presence is a major determinant of adverse clinical outcomes. As a potentially treatable cause of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction, the early recognition of FD is crucial to initiate enzyme replacement therapy and improve long-term prognosis. Multimodality imaging plays a central role in the evaluation of patients with FD and helps in the differential diagnosis of other conditions presenting with LVH. In the present review, we explore the current applications of multimodality cardiac imaging, in particular echocardiography and cardiovascular magnetic resonance, in the diagnosis, prognostic assessment, and follow-up of patients with FD.
Stankowski et al. (Mon,) conducted a review in Fabry disease. Multimodality cardiac imaging was evaluated. Multimodality cardiac imaging, particularly echocardiography and cardiovascular magnetic resonance, plays a central role in the diagnosis, prognostic assessment, and follow-up of Fabry disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: